Pacific Bio (NASDAQ: PACB) reported Q4 EPS of ($0.35), in-line with the analyst estimate of ($0.35). Revenue for the quarter came in at $27.4 million versus the consensus estimate of $26.59 million.

For earnings history and earnings-related data on Pacific Bio (PACB) click here.